Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

Impact · against what's priced in

Utah Medical Products faces a negative outlook following a double-digit decline in revenue and EPS. The loss of two major customers, including PendoTECH, creates a structural revenue gap that outweighs the company's stable gross margins.

UTMD−0.30: No priced-in read yet
In context: Revenue fell 14.3% to $8.5 million and EPS dropped 10.1% to 84.4 cents, driven by the total loss of two major customers including PendoTECH.
Read from the article alone

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

earnings
healthcare
UTMD
medical devices
microcap

Search tags

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

What matters in this story

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

What matters in this story

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

How each ticker is affected

Track these names every morning.

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Curaleaf Unlikely To Acquire Aurora Cannabis, But Long-Term Potential Remains

VIAV's Q1 Beat and Q2 Outlook Highlight Data Center Momentum Ahead

AECOM Q4 Earnings Ahead: What Should Investors Expect?

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

What matters in this story

Next reads from the same story arc

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

What matters in this story

Next reads from the same story arc

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

How each ticker is affected

Track these names every morning.

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Curaleaf Unlikely To Acquire Aurora Cannabis, But Long-Term Potential Remains

VIAV's Q1 Beat and Q2 Outlook Highlight Data Center Momentum Ahead

AECOM Q4 Earnings Ahead: What Should Investors Expect?